Rituximab induced psoriasis in an infant.
Rituximab is a chimeric monoclonal antibody directed against the CD20 antigen present on the surface of mature B cells. It has been widely used in the treatment of many dermatologic and rheumatologic conditions. The onset of psoriasis after rituximab therapy has not been reported in children. We report the first case of psoriasis after rituximab therapy in a 16-month-old boy with no other risk factors for developing psoriasis.